Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phase I Clinical Trials Insurance Guidance Published

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
ABPI, BIA and CCRA jointly publish guidance.

The Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA) and the Clinical Contract Research Association (CCRA) have jointly published guidance on insurance and compensation for Phase I clinical trials.

The guidance, which has been developed in consultation with the Department of Health and the National Research Ethics Service (NRES) within the Health Research Authority (HRA), is for trials including first-in-man studies involving healthy volunteers.

The guidance also applies to studies conducted in patient volunteers without the target disease to provide additional pharmacokinetic data about the medicine under research.

The guidance is intended for use by Phase I clinical trial sponsors, clinical research organizations and ethics committees. It has been developed to provide authoritative recommendations on the level of insurance and other aspects of insurance cover.

The guidance is based on industry best practice and complements wider industry guidance on conducting Phase I clinical studies.

It will provide assurance to volunteers in clinical trials and ethics committees that adequate insurance is in place. This will accelerate the ethics committee review process, enabling clinical trials to start more quickly, and thereby enhancing the clinical development environment in the UK.

Published alongside the guidance is a template Statement of Insurance Cover, which has been developed by NRES, to give clinical trial sponsors a consistent document to provide to the ethics committee.

The statement will be incorporated into the standard application for Phase I clinical trials within the Integrated Research Application System for health and social care research in the UK.

Dr Janet Wisely, Chief Executive at the HRA, said: "The HRA welcomes the publication of these guidelines, which provide a robust source of guidance to Research Ethics Committees on insurance in Phase I clinical trials and will help to ensure that the interests of volunteers are properly protected."

Stephen Whitehead, Chief Executive at the ABPI, said: "Building on the original ABPI insurance guidance, we are pleased to develop with our partner associations, the joint ABPI-BIA-CCRA guidance. Appropriate insurance arrangements recognize the role of volunteers in developing new medicines and we believe the template will provide clear information to regulators."

Glyn Edwards, Interim Chief Executive at the BIA, said: "This guidance recognizes the importance of volunteers in the development of new treatments and is another step to demonstrating that the UK remains a key location for conducting clinical trials. The use of the template document should help accelerate the initiation of trials and the BIA recommends its use to our members."

Professor Atholl Johnston, President of the CCRA, said: "We welcome the publication of these guidelines which, again, underline the UK's commitment to the highest standards in clinical trials where safeguarding the interests of volunteers is a prime concern.

"The use of the template will add to the excellent initiatives already in place to speed the commencement of clinical trials in the UK."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Political Agreement on EU Clinical Trial Regulation Simplifies Rules But Misses its Initial Goal
UK patients miss out the chance to participate in developing the therapies of the future.
Monday, December 23, 2013
Two UK Companies Shortlisted for EuropaBio Most Innovative EU Biotech SME Award
e-Therapeutics and PsiOxus Therapeutics have received two year's free membership of EuropaBio.
Monday, September 23, 2013
SynbiCITE Will Strengthen the UK's Burgeoning Synbio Sector
Imperial College is to host SynbiCITE - a new £10 million Innovation and Knowledge Centre for synthetic biology.
Thursday, July 11, 2013
Synthetic Biology Companies join BIA, Trade Association Forms New Group for Emerging Sector
Eight synthetic biology (synbio) companies have joined the BioIndustry Association (BIA) to form a new group working on this emerging area of bioscience.
Thursday, April 04, 2013
BIA and bioProcessUK Welcome GlaxoSmithKline Manufacturing Investment
GlaxoSmithKline to invest £500 million in manufacturing facilities in the UK.
Monday, September 24, 2012
Academy of Medical Sciences Report: A Step in the Right Direction
The BioIndustry Association (BIA) welcomes the publication of a report by the Academy of Medical Sciences (AMS) which recommends urgent changes to the regulation and governance of health research in the UK.
Tuesday, January 11, 2011
Growth Review Highlights Life Sciences as a Key Sector; Confirms Introduction of Patent Box and Reviews R&D Tax Credits
The government’s growth review “The path to strong, sustainable and balanced growth", launched today by the Chancellor of the Exchequer, George Osborne, is a promising road map to enable the UK to build its vibrant life sciences sector.
Tuesday, November 30, 2010
Industry Concerns Over Human Tissue Authority (HTA) Licence Fee Increases
The BioIndustry Association (BIA), the Association of British Healthcare Industries (ABHI) and the British In Vitro Diagnostics Association (BIVDA) express their grave concern that the Human Tissue Authority (HTA) intends to introduce licence fee increases of up to more than three times 2008 rates for companies using human tissue.
Tuesday, March 31, 2009
Access to Capital Challenges Future of UK Life Sciences Industry – Urgent Government Investment Required
Between 12 and 20 March 2009 the BioIndustry Association (BIA) conducted a survey on the financing of the life sciences industry including therapeutic, diagnostic and devices companies.
Monday, March 30, 2009
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!